CVS Health Corporation $CVS Shares Bought by NewEdge Wealth LLC

NewEdge Wealth LLC grew its holdings in shares of CVS Health Corporation (NYSE:CVS) by 48.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 25,099 shares of the pharmacy operator’s stock after purchasing an additional 8,200 shares during the quarter. NewEdge Wealth LLC’s holdings in CVS Health were worth $1,992,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CVS. National Pension Service boosted its holdings in shares of CVS Health by 3.1% during the 3rd quarter. National Pension Service now owns 3,999,622 shares of the pharmacy operator’s stock worth $301,532,000 after purchasing an additional 119,189 shares during the last quarter. Kingsview Wealth Management LLC boosted its position in shares of CVS Health by 316.2% during the 3rd quarter. Kingsview Wealth Management LLC now owns 104,432 shares of the pharmacy operator’s stock valued at $7,873,000 after acquiring an additional 79,340 shares during the last quarter. AE Wealth Management LLC boosted its position in shares of CVS Health by 6.2% during the 3rd quarter. AE Wealth Management LLC now owns 257,204 shares of the pharmacy operator’s stock valued at $19,391,000 after acquiring an additional 14,983 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of CVS Health by 11.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 225,116 shares of the pharmacy operator’s stock valued at $16,971,000 after acquiring an additional 22,653 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its position in shares of CVS Health by 186.6% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 396,368 shares of the pharmacy operator’s stock valued at $30,568,000 after acquiring an additional 258,050 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: JPMorgan and Sanford C. Bernstein both raised their price targets on CVS and kept bullish ratings, signaling confidence that the stock still has room to run after its strong Q1 results. JPMorgan and Bernstein price target updates
• Positive Sentiment: TD Cowen also lifted its target and reiterated a buy rating, adding to the recent analyst optimism around CVS Health’s earnings momentum and raised full-year guidance. TD Cowen adjusts price target on CVS Health to 110 from 105
• Positive Sentiment: Recent commentary says CVS is still cheap relative to its improving earnings, revenue growth, and margins, with Q1 showing better profitability and management raising 2026 guidance. CVS Health: Still Cheap And Signs Of Improvement
• Positive Sentiment: CVS is also benefiting from business updates that favor lower-cost biosimilars in its commercial formularies, which could support cost control and improve competitiveness in pharmacy benefits. CVS Health Corporation Updates its Commercial Formularies
• Neutral Sentiment: The company disclosed insider selling by EVP Tilak Mandadi, who sold 69,551 shares. The size is notable, but it does not necessarily indicate a change in the company’s outlook. SEC Form 4 filing
• Neutral Sentiment: Additional articles and market chatter continue to highlight CVS as a value and dividend name, reinforcing the bullish tone but not adding a major new catalyst. CVS Health is a Top-Ranked Growth Stock

Wall Street Analyst Weigh In

CVS has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft boosted their price target on shares of CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Argus decreased their price objective on CVS Health from $91.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, January 28th. Royal Bank Of Canada upped their price objective on CVS Health from $93.00 to $107.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. The Goldman Sachs Group upped their price objective on CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a report on Thursday, February 12th. Finally, HSBC upped their price objective on CVS Health from $83.00 to $85.00 and gave the company a “hold” rating in a report on Tuesday, May 5th. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, CVS Health has an average rating of “Moderate Buy” and a consensus price target of $97.00.

Insider Activity

In other news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the sale, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.85% of the company’s stock.

CVS Health Stock Up 3.2%

Shares of CVS opened at $95.19 on Wednesday. The stock has a market capitalization of $121.45 billion, a PE ratio of 41.93, a P/E/G ratio of 0.90 and a beta of 0.60. CVS Health Corporation has a 1 year low of $58.35 and a 1 year high of $95.36. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The company’s 50-day simple moving average is $77.74 and its 200-day simple moving average is $78.24.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. The business had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Analysts forecast that CVS Health Corporation will post 7.46 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were paid a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Thursday, April 23rd. CVS Health’s dividend payout ratio (DPR) is presently 117.18%.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.